The estimated Net Worth of Nishan M De Silva is at least $136 Tausend dollars as of 2 December 2021. Nishan Silva owns over 7,000 units of Selecta Biosciences Inc stock worth over $6,160 and over the last 13 years Nishan sold SELB stock worth over $129,582.
Nishan has made over 4 trades of the Selecta Biosciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Nishan bought 7,000 units of SELB stock worth $20,720 on 2 December 2021.
The largest trade Nishan's ever made was exercising 68,363 units of Selecta Biosciences Inc stock on 12 May 2015 worth over $2,404,327. On average, Nishan trades about 7,076 units every 280 days since 2012. As of 2 December 2021 Nishan still owns at least 7,000 units of Selecta Biosciences Inc stock.
You can see the complete history of Nishan Silva stock trades at the bottom of the page.
Nishan's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 65 GROVE STREET, WATERTOWN, MA, 02472.
Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit... und Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Selecta Biosciences Inc executives and other stock owners filed with the SEC include: